SUSVIMO®: now available for the treatment of diabetic retinopathy (DR).
SUSVIMO®: now available for the treatment of diabetic retinopathy (DR).
For people with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have responded to at least two injections of a vascular endothelial growth factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
†In a clinical trial, 248 people received SUSVIMO, while 167 people were treated with monthly ranibizumab injections. On average, people on SUSVIMO were able to maintain similar vision results to those receiving monthly ranibizumab injections over 1 year.
‡There was a temporary decrease in vision following the SUSVIMO procedure; however, your vision will return to normal as your eye recovers from the procedure.
What would fewer treatments with SUSVIMO® mean for you?
For Dawn it means she could spend time on her famous sweaters… a real family favourite
Eleanor could stop worrying about making it to her monthly injections
Jim could focus on hitting all the right notes… much to his partners delight
And Kenny could swap injection appointments for more “you got this dad” moments
If you have wet AMD or DME, you can enjoy the same vision results as your current treatment with just 2 refills a year
And if you have DR, you can significantly improve your disease with a refill once every 9 months
Discover what your future holds with SUSVIMO®
Continuous treatment, EVERYWHERE YOU GO
What is SUSVIMO (ranibizumab injection)?
SUSVIMO (ranibizumab injection) is a prescription medicine used to treat adults with neovascular (wet) Age-related Macular Degeneration (AMD) who have responded to at least two injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal). It is not known if SUSVIMO is safe and effective in children.
What is the most important information I should know about SUSVIMO?
SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill, and remove the eye (ocular) implant can cause serious side effects, including:
An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, eye discharge, or watering of the eye. Conjunctival retraction may require surgical treatment.
Do not receive SUSVIMO if you:
Talk to your healthcare provider before receiving SUSVIMO if you have any of these conditions.
Before receiving SUSVIMO, tell your healthcare provider about all of your medical conditions, including if you:
What are other possible side effects of SUSVIMO?
The SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause other serious side effects, including:
Tear and separation of layers of the retina (rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Call your healthcare provider or go to the emergency room right away if you see flashing lights, see a curtain or veil covering part of your vision, or have a change in, or a loss of vision. Rhegmatogenous retinal detachment requires surgical treatment.
Implant movement (implant dislocation): Tell your healthcare provider right away if you notice that the implant has moved out of place. This movement may require surgical treatment to correct.
Implant damage: Damage to the implant that prevents continued treatment (refills) with SUSVIMO. If the implant is not able to be properly refilled, your wet AMD may be inadequately treated and your physician may remove the implant and/or change your treatment.
Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. Call your healthcare provider right away if you have an increase in moving spots or what looks like spider webs in your vision, as you may need an additional eye surgery.
Bump on top of the white layer of the eye (conjunctival bleb): conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. Call your healthcare provider right away if you have a sudden feeling that something is in your eye (foreign body sensation), see a bulge over the white part of your eye, have eye discharge, or have watering in the eye. You may need medical or surgical treatment.
Temporary decrease in vision after the SUSVIMO procedure.
The most common side effects of SUSVIMO include:
These are not all the possible side effects of SUSVIMO.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888- 835-2555.
Please see Important Safety Information, including Serious Side Effects, as well as the SUSVIMO full Prescribing Information and Medication Guide.
For people with neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have responded to at least two injections of a vascular endothelial growth factor (VEGF) inhibitor in the gel-like part of the eye (intravitreal).
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.